April 23, 2018 / 9:23 PM / 6 months ago

BRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration

April 23 (Reuters) - Celgene Corp:

* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION

* ZYMEWORKS INC - CELGENE CORP EXERCISED RIGHT TO EXPAND DEAL FOR COMMERCIALIZATION OF BISPECIFIC ANTIBODY THERAPEUTICS USING CO’S AZYMETRIC PLATFORM

* ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE AN EXPANSION FEE

* ZYMEWORKS INC - IN TOTAL, ZYMEWORKS IS NOW ELIGIBLE TO RECEIVE UP TO $1.64 BILLION IN FUTURE PAYMENTS FOR ENTIRE COLLABORATION

* ZYMEWORKS INC - CELGENE HAS EXERCISED ITS RIGHT TO INCREASE NUMBER OF POTENTIAL PRODUCTS IT CAN DEVELOP AND COMMERCIALIZE FROM EIGHT TO TEN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below